Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly and Co demonstrated strong financial performance across several key segments, with reported organic revenue growth of 8.0% in MedSurgEndoscopy and a notable 16.1% increase in cardiovascular revenues during Q4. The company particularly excelled in electrophysiology, achieving a remarkable 35% organic growth year-over-year, supported by favorable market expansion projections for the sector. Furthermore, neuromodulation revenues increased by 10% and urology revenues grew by 3.0%, reinforcing Eli Lilly's robust positioning and growth trajectory in the pharmaceutical industry.

Bears say

Eli Lilly and Co's stock faced an 18% decline following the company's guidance for 2026, which was perceived as weak, particularly in its electrophysiology (EP) business that failed to meet fourth-quarter consensus expectations. The company is experiencing concerns regarding slower-than-expected uptake of its portfolio and potential pricing pressures, alongside risks related to the performance of its key drug, Mounjaro, in the cardiovascular market. Additionally, the downside scenario outlined suggests higher debt levels and limited operational leverage, casting further doubt on the company's ability to achieve its stated financial goals by 2028.

Eli Lilly (LLY) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 17 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,159.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,159.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.